The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Public ClinicalTrials.gov record NCT03896958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any medical facility. Tumor tissue is saved at time of biopsy or surgery in multiple formats, including fresh and cryopreserved as a living biospecimen. SpeciCare assists with access to clinical records in order to provide information back to the patient and the patient's clinical care team. The biospecimen tumor tissue is stored in a bio-storage facility and can be shipped anywhere the patient and the clinical team require for further testing. Additionally, the cryopreservation of the biospecimen allows for decisions about testing to be made at a later date. It also facilitates participation in clinical trials. The ability to return research information from this repository back to the patient is the primary end point of the study. The secondary end point is the subjective assessment by the patient and his or her physician as to the potential benefit that this additional information provides over standard of care. Overall the goal of PIONEER is to enable best in class functional precision testing of a patient's tumor tissue to help guide optimal therapy (to date this type of analysis includes organoid drug screening approaches in addition to traditional genomic profiling).
Study identification
- NCT ID
- NCT03896958
- Recruitment status
- Not listed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
- Cancer, All Types
- Cancer of Liver
- Cancer of Stomach
- Cancer of Head and Neck
- Cancer of Rectum
- Cancer of Kidney
- Cancer of Esophagus
- Cancer of Colon
- Cancer Skin
- Cancer of Cervix
- Cancer, Metastatic
- Cancer of Larynx
- Cancer of Neck
- Cancer of Lung
- Cancer of Brain and Nervous System
- Cancer of Vulva, Disseminated
- Cancer of Pancreas
- Sarcoma
- GIST
- Small-cell Lung Cancer
- Adenocarcinoma Lung
- Cancer of Prostate
- Cancer, Advanced
- Adrenal Cancer
- Testicular Cancer
- Uterine Cancer
- Bronchoalveolar Cell Lung Cancer
- Cancer Unknown Primary
- Glioblastoma Multiforme
- Oligodendroglioma
- Breast Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Cholangiocarcinoma
- Squamous Cell Carcinoma
- Transitional Cell Carcinoma
- Cancer, Other
- Cancer, Anal
- Melanoma
- Cancer, Bile Duct
- Cancer, Bladder
- Cancer Cords Vocal
- Cancers Cell Neuroendocrine
- Cancer Differentiated Poorly
- Cancer, Anaplastic Thyroid
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 1 Month to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2019
- Primary completion
- Mar 11, 2024
- Completion
- Mar 11, 2024
- Last update posted
- Dec 3, 2020
2019 – 2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Specicare | Gainesville | Georgia | 30501 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03896958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2020 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03896958 live on ClinicalTrials.gov.